Question 1

Am I eligible to participate in this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) clinical trial (NCT06863272). Contact the study team or your healthcare provider for specific answers.

Question 2

How does Ifinatamab Deruxtecan compare to my current treatments?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) clinical trial (NCT06863272). Contact the study team or your healthcare provider for specific answers.

Question 3

What side effects should I expect from this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) clinical trial (NCT06863272). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come for visits if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) clinical trial (NCT06863272). Contact the study team or your healthcare provider for specific answers.

Question 5

What tests and monitoring will be required during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) clinical trial (NCT06863272). Contact the study team or your healthcare provider for specific answers.

Question 6

Can you explain how you will assess the effectiveness of the treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) clinical trial (NCT06863272). Contact the study team or your healthcare provider for specific answers.

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

What this study is about

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

What this study is about